History
1992
Peace Pharmaceutical Factory has formed a joint venture with Hong Kong Yingjie Co., Ltd. to establish “Xinxiang Zhongjie Pharmaceutical Co., Ltd.”
1993
Officially obtained the business license for corporate legal persons.
1995
Obtain a pharmaceutical manufacturing enterprise license.
1996
Obtain the qualification certificate for pharmaceutical manufacturing enterprises.
2000
Gliclazide tablets have successively won the Xinxiang City Outstanding New Product Award and the Second Prize for Pharmaceutical Science and Technology Progress in Henan Province. Ruipailing has been awarded the Second Prize for Outstanding Products in Xinxiang City.
2002
Acquired the No. 1 Branch of Xinxiang Wehe Pharmaceutical Factory through merger, obtaining approval for 17 product registrations—including 5 dosage forms—such as Shenjin Huoluo Wan.
2003
The production scope has been expanded to cover six major dosage forms. The workshop for comprehensive oral solid dosage forms of Western medicines successfully passed the on-site inspection and acceptance in one go, and has obtained the company’s GMP certification. The modernized production line for traditional Chinese medicine has been put into operation.
2004
The pre-processing and extraction facilities for traditional Chinese medicine, as well as the Chinese medicinal preparation workshop, have successfully passed the on-site inspection for GMP certification by the Henan Provincial Administration for Market Regulation of Food and Drugs and have been awarded the GMP certificate.
2005
Lianpu Shuangqing Tablets and Chitong Xiaoyanling Granules have been designated as “China’s Protected Varieties of Traditional Chinese Medicine”; Shenjin Huoluo Pills have been included in the “Henan Province 2005 Torch Program”; and the Xiaoai Ping series of products have received new drug certificates and approvals.
2009
“Xinxiang Zhongjie Pharmaceutical Co., Ltd.” has been officially renamed “Henan Zhongjie Pharmaceutical Co., Ltd.”
2019
The high-tech enterprise certification has been approved. Five generic drugs—Gliclazide Tablets, Warfarin Sodium Tablets, Indapamide Tablets, Sodium Diclofenac Enteric-Coated Tablets, and Betahistine Hydrochloride Tablets—are participating in quality and efficacy assessments and have initiated consistency evaluations.
2020
Both output value and sales have surpassed 200 million yuan, maintaining a year-on-year growth of 13% despite the impact of the pandemic. The “Abdominal and Imaging Diagnostic Agents” project has been launched at the Bashan plant.
2021
The Betahistine Hydrochloride Tablets have passed the consistency evaluation, making our company the second in the country to achieve this milestone. Our company’s output value has exceeded 250 million yuan, and we now have over 700 cooperative clients.
2022
The construction of the new 30,000-square-meter Huamei Chinese Medicine Health Industry Park has commenced, and the “Intelligent Integrated Production and Storage System Construction Project” has been launched. At the same time, a “One Body, Two Wings” plan—centered on the Bashan plant and with Zhongjie and Huamei as its two wings—is also being initiated.
2023
Received the “Henan Province Specialized, Sophisticated, and New Small and Medium-sized Enterprise” designation awarded by the Henan Provincial Department of Industry and Information Technology. The company’s output value has exceeded 300 million yuan, and the intelligent dispatch center for the “Integrated Production and Storage System Construction Project” is now ready for operation. The Bashan plant has been officially completed and has obtained a production license.
2024
The intelligent operations and dispatch center has been completed, with a production capacity reaching 7 billion tablets/capsules per year.
Investment Hotline： +86-4001336009
Drug Vigilance Department Contact Hotline：
Address：Xinxiang South Railway Station, Xinxiang City, Henan Province
E-mail：zhongjieyaoye@126.com
Official WeChat
Official Douyin
Copyright © Henan Zhongjie Pharmaceutical Co., Ltd.
Privacy Agreement Supports IPV6 SEO